XIAP 和 P-糖蛋白的共表达与慢性髓性白血病细胞对伊马替尼的耐药性有关。
XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells.
机构信息
Laboratório de Hemato-Oncologia Celular e Molecular, Programa de Hemato-Oncologia Molecular, Coordenação Geral Técnico-Científica, Instituto Nacional de Câncer and Programa de Pós-Graduação em Oncologia/INCA, Brazil.
出版信息
Leuk Res. 2013 Oct;37(10):1350-8. doi: 10.1016/j.leukres.2013.06.014. Epub 2013 Jul 25.
P-glycoprotein (Pgp) and XIAP co-expression has been discussed in the process of the acquisition of multidrug resistance (MDR) in cancer. Here, we evaluated XIAP and Pgp expression in chronic myeloid leukemia (CML) samples, showing a positive correlation between them. Furthermore, we evaluated the effects of imatinib in XIAP and Pgp expression using CML cell lines K562 (Pgp(-)) and K562-Lucena (Pgp(+)). Imatinib increased XIAP and Pgp expression in K562-Lucena cells, while in K562 cells a downregulation of these proteins was observed, suggesting that imatinib induces an increment of MDR phenotype of CML cells that previously exhibit high levels of Pgp/XIAP co-expression.
多药耐药（MDR）的获得过程中曾讨论过 P-糖蛋白（Pgp）和 XIAP 的共表达。在此，我们评估了慢性髓性白血病（CML）样本中的 XIAP 和 Pgp 表达，发现它们之间呈正相关。此外，我们使用 CML 细胞系 K562（Pgp(-)）和 K562-Lucena（Pgp(+)）评估了伊马替尼对 XIAP 和 Pgp 表达的影响。伊马替尼增加了 K562-Lucena 细胞中 XIAP 和 Pgp 的表达，而在 K562 细胞中观察到这些蛋白的下调，表明伊马替尼诱导先前表现出高水平 Pgp/XIAP 共表达的 CML 细胞 MDR 表型的增加。
Zotero 插件